Drugs / RHN-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05847218 | Mar 2023 | — | RH Nanopharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RHN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05847218 ↗ |
| Route | Oral | “1500 mg of RHN-001 administered orally” NCT05847218 ↗ |